Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

Hepatocellular carcinoma (HCC) is the strongest independent predictor of mortality in non-alcoholic steatohepatitis (NASH)-related cirrhosis. The effects and mechanisms of combination of sodium-dependent glucose cotransporter inhibitor and canagliflozin (CA) and dipeptidyl peptidase-4 inhibitor and...

Full description

Bibliographic Details
Main Authors: Takahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Masanori Furukawa, Keisuke Nakanishi, Shinya Sato, Yasuhiko Sawada, Soichiro Saikawa, Koh Kitagawa, Hiroaki Takaya, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya, Ryuichi Noguchi, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:International Journal of Molecular Sciences
Subjects:
non-alcoholic steatohepatitis
hepatic fibrogenesis
hepatocarcinogenesis
canagliflozin
teneligliptin
Online Access:https://www.mdpi.com/1422-0067/21/6/2164

Internet

https://www.mdpi.com/1422-0067/21/6/2164

Similar Items